3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Acrocephalosyndactylia
6
Cholangiocarcinoma
4
Neoplasm Metastasis
3
Myeloproliferative Disorders
2
Endometrial Neoplasms
2
Carcinoma, Transitional Cell
2
Stomach Neoplasms
1
Solid Tumor
1
Recurrence
1
Oligodendroglioma
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Multiple Myeloma
1
Lung Neoplasms
1
Glioma
1
Glioblastoma
1
Eosinophilia
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Advanced Malignancies
1
Interventions
Dexamethasone
64
Cyclophosphamide
35
pomalidomide
34
Lenalidomide
34
Rituximab
31
Bortezomib
30
venetoclax
28
fludarabine
27
Gemcitabine
21
carfilzomib
20
Paclitaxel
19
pembrolizumab
17
daratumumab
17
Cisplatin
16
Carboplatin
15
Calcium Dobesilate
14
Azacitidine
14
ibrutinib
12
Docetaxel
12
Cytarabine
12
obinutuzumab
11
Nivolumab
11
durvalumab
10
Injections
10
Doxorubicin
10
Bevacizumab
10
selinexor
9
cemiplimab
9
blinatumomab
9
Cetuximab
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Recurrence
×
pemigatinib
×
Clear all
NCT05253807
2025-08-05
FIGHT-210
Incyte Corporation
Phase 2
Completed
8 enrolled
13 charts